Hot Biotech Sector: Mid-Caps Have Both M&A and Pipeline Premiums
Valuations Step-Up With More Deals Prior to the acquisition of Pharmacyclics (PCYC) by Abbvie (ABBV) for $20B, the top price paid for an emerging biotech company was in the $10B range. Two additional companies among the mid-caps were acquired in prior years: Cubist by Merck in December 2014...
Biotechs Tag Along With Broad Market Rally: FBT Up 3%
Jobs Report Drive Stocks Higher-DOW Up 1.5% Stocks moved higher on the “goldilocks” job report which showed a gain of 223k added in April. The jobs number was too high to raise concerns about an increase in rates but not too bullish because overall productivity is down. Jobless...
M&A Sparks Biotechs: Alexion Buys Syngeva for $8.4B…Update-1
Orphan Drugs-The Latest Hot Spot in Biotech Large Cap Biotechs Were Red-Specualtive Stocks Were Green XBI 214.9 up 2.36% GEVA $203.4 up 112% NASDAQ 4919 down 0.4% Rare Disease Companies Merge: ALXN and GEVA Alexion Pharmaceuticals (ALXN) the leading company in severe and life threatening...
Surveying the Damage with Rayno Life Science Stocks…2015 YTD
Biotech Bounce-Caution on New Positions IBB up 2% at 340 support level Most biotech stocks are green as of early trading on May 1. Although the sector has taken a beating since April 23 most ETFs and funds are outperforming the market year to date up more than 10%. As we posted earlier this...
Biotech Buzz Is Broken…Update 4/30…#2
Gilead (GILD) Gilead Beats Q1 Estimates: $7.4B Sales HCV , EPS $2.94, stock up 2% after hours XBI Down Another 4% Down 12.84% in Five Days Weak Tape and Sell-Off Continues…4/30…NASDAQ at 4991 XBI down 1.6% now at 2/24 lows at 212 High fliers hit with profit taking…ADRO, AGIO,...